AAAAAA
Results:
1-8
|
Results: 8
Authors:
Cummings, JL
Nadel, A
Masterman, D
Cyrus, PA
Citation: Jl. Cummings et al., Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease, J GER PSY N, 14(2), 2001, pp. 101-108
Authors:
Farlow, MR
Cyrus, PA
Citation: Mr. Farlow et Pa. Cyrus, Metrifonate therapy in Alzheimer's disease: A pooled analysis of four randomized, double-blind, placebo-controlled trials, DEMENT G C, 11(4), 2000, pp. 202-211
Authors:
Blass, JP
Cyrus, PA
Bieber, F
Gulanski, B
Citation: Jp. Blass et al., Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer disease, ALZ DIS A D, 14(1), 2000, pp. 39-45
Authors:
Gelinas, I
Gauthier, S
Cyrus, PA
Citation: I. Gelinas et al., Metrifonate enhances the ability of Alzheimer's disease patients to initiate, organize, and execute instrumental and basic activities of daily living, J GER PSY N, 13(1), 2000, pp. 9-16
Authors:
Raskind, MA
Cyrus, PA
Citation: Ma. Raskind et Pa. Cyrus, Metrifonate for Alzheimer's disease patients - Drs. Raskind and Cyrus reply, J CLIN PSY, 61(3), 2000, pp. 218-219
Authors:
Raskind, MA
Cyrus, PA
Ruzicka, BB
Gulanski, BI
Citation: Ma. Raskind et al., The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients, J CLIN PSY, 60(5), 1999, pp. 318-325
Authors:
Jann, MW
Cyrus, PA
Eisner, LS
Margolin, DI
Griffin, T
Gulanski, B
Citation: Mw. Jann et al., Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: A randomized, double-masked, placebo-controlled trial, CLIN THER, 21(1), 1999, pp. 88-102
Authors:
Farlow, MR
Cyrus, PA
Nadel, A
Lahiri, DK
Brashear, A
Gulanski, B
Citation: Mr. Farlow et al., Metrifonate treatment of AD - Influence of APOE genotype, NEUROLOGY, 53(9), 1999, pp. 2010-2016
Risultati:
1-8
|